| Annual · values | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Gross Margin | 9.65% | 5.40% | 15.47% | 39.53% | 48.69% | 35.42% |
| Operating Margin | -335.40% | -337.56% | -455.87% | -242.83% | -220.63% | -261.92% |
| EBITDA Margin | -320.84% | -319.16% | -440.32% | -238.52% | -218.09% | -260.37% |
| Net Margin | -342.78% | -399.98% | -647.57% | -269.92% | -241.75% | -281.63% |
| Current Ratio | — | — | — | — | — | — |
| Quick Ratio | — | — | — | — | — | — |
| Debt / Equity | 0.34 | 0.71 | 0.24 | 6.21 | -11.13 | -19.17 |
| ROE | -146.20% | -314.24% | -257.41% | -1017.53% | 1421.50% | 4965.68% |
| ROA | -85.00% | -131.78% | -157.64% | -106.72% | -102.44% | -138.23% |
| Asset Turnover | 0.25 | 0.33 | 0.24 | 0.40 | 0.42 | 0.49 |
| Book Value / Share | 1.49 | 4.43 | 132.40 | 158.15 | -148.61 | -43.92 |
Viveve Medical Inc. specializes in the design, development, manufacturing, and marketing of medical devices primarily focused on women's health. Its flagship product, the Viveve System, employs Cryogen-cooled Monopolar Radiofrequency technology for non-invasive treatments addressing vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. This innovative medical technology plays a significant role in enhancing women's well-being by offering low-risk, high-reward procedures. Viveve Medical Inc. operates across a global network, including the Americas, Europe, and Asia-Pacific regions, making it a notable player in the healthcare sector, particularly within the medical devices industry.